Xiphora Biopharma Consulting is a UK-based consultancy offering nonclinical services to the pharmaceutical sector.
Our services include Nonclinical Drug Development and Specialist Consulting.
The principal, David Snodin, PhD, is a regulatory pharmacotoxicologist with over 35 years’ experience in industry, government and consulting.
As well as general nonclinical consulting, we specialize in dealing with issues at the Quality-Safety interface, particularly impurity qualification, synthetic-route assessment for mutagenic impurities and the safety assessment of novel excipients. In addition, we provide advice on Environmental Risk Assessment, e-cigarettes and PDE (Permitted Daily Exposure) determination in relation to health-based exposure limits.
For more information please select Services from the menu above.